Integrated Proteins reported a net profit of ₹21.30 lakh for the financial year ended March 31, 2026, compared to ₹22.50 lakh in the previous year. Revenue from operations for FY26 stood at ₹2,152.56 lakh, a significant increase from ₹994.07 lakh in FY25. The board approved the audited standalone financial results during a meeting held on May 26, 2026, at the company's registered office in Jamnagar.

The statutory auditors, M/s B. B. Gusani & Associates, issued an unmodified opinion on the financial results. For the quarter ended March 31, 2026, the company recorded a net profit of ₹23.14 lakh on a total income of ₹569.53 lakh. The earnings per share (EPS) for the year was ₹0.11, compared to ₹0.12 in the previous year.

Financial Performance

The company's total expenses for FY26 amounted to ₹2,125.15 lakh, up from ₹965.74 lakh in the prior year. The profit before tax for the year was ₹27.41 lakh, slightly lower than the ₹28.33 lakh reported in FY25. The finance costs remained nil for both the quarter and the year under review.

Segment-wise Results

Integrated Proteins operates across multiple segments including Agro & Trading, Textile, Securities, and Medical. The Textile segment contributed ₹461.63 lakh to the revenue in the quarter ended March 31, 2026. The Securities segment reported a profit before tax of ₹19.89 lakh for the same period.

Balance Sheet and Cash Flow

The company's equity share capital increased to ₹1,903.02 lakh as of March 31, 2026, from ₹352.02 lakh in the previous year, due to the allotment of shares during the year. Total assets stood at ₹2,061.08 lakh, a decrease from ₹3,237.23 lakh in FY25. The cash and cash equivalents as at the end of the year were negative at ₹(1.56) lakh.

Net cash flow from operating activities for FY26 was ₹360.26 lakh, compared to a net outflow of ₹(2,356.51) lakh in the previous year. The company utilized ₹370.55 lakh in financing activities, primarily due to the repayment of short-term borrowings.

Integrated Proteins Limited has submitted its quarterly compliance certificate to BSE Limited in accordance with SEBI regulations for the quarter ended March 31, 2026. The submission fulfills the company's regulatory obligations under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Submission

The certificate was submitted under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, dated April 11, 2026. Managing Director Karanj Dharmeshbhai Doshi signed the submission letter to BSE Limited, ensuring proper documentation of the company's compliance status.

Registrar Confirmation

Cameo Corporate Services Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate on April 1, 2026. The certificate confirms that all securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to the depositories.

The registrar confirmed several key compliance aspects:

• Securities received for dematerialisation were accepted or rejected appropriately
• All securities in the certificates have been listed on stock exchanges where previously issued securities are traded
• Security certificates received for dematerialisation were mutilated and cancelled after proper verification
• Depository names were substituted in the register of members as registered owners within stipulated time limits

Corporate Information

Integrated Proteins Limited operates from Manek Centre, Office No 218, P N Marg, Jamnagar, Gujarat. The company maintains its corporate identification number as L62013GJ1992PLC018426 and trades on BSE with scrip code 519606. The quarterly submission demonstrates the company's commitment to maintaining regulatory compliance and transparent corporate governance practices.